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E-mail address: gwhart@jhmi.edu (G.W. Hart).Ser(Thr)-O-linked b-N-acetylglucosamine (O-GlcNAc) is a ubiquitous modiﬁcation of nucleocytoplas-
mic proteins. Extensive crosstalk exists between O-GlcNAcylation and phosphorylation, which reg-
ulates signaling in response to nutrients/stress. The development of novel O-GlcNAc detection and
enrichment methods has improved our understanding of O-GlcNAc functions. Mass spectrometry
has revealed O-GlcNAc’s many interactions with phosphorylation-mediated signaling. However,
mechanisms regulating O-GlcNAcylation and phosphorylation are quite different. Phosphorylation
is catalyzed by hundreds of distinct kinases. In contrast, in mammals, uridine diphospho-N-acetyl-
glucosamine:polypeptide b-N-acetylglucosaminyl transferase (OGT) and b-D-N-acetylglucosamini-
dase (OGA) are encoded by single highly conserved genes. Both OGT’s and OGA’s speciﬁcities are
determined by their transient associations with many other proteins to create a multitude of spe-
ciﬁc holoenzymes. The extensive crosstalk between O-GlcNAcylation and phosphorylation repre-
sents a new paradigm for cellular signaling.
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O-GlcNAcylation is a common posttranslational modiﬁcation
(PTM) of nuclear and cytosolic proteins. O-GlcNAcylation was ser-
endipitously discovered in experiments designed to detect termi-
nal GlcNAc residues on the surfaces of living lymphocytes, but
surprisingly nearly all of the O-GlcNAc was found to be on nucleo-
cytoplasmic proteins, where dogma said protein glycosylation was
absent [1,2]. O-GlcNAcylation occurs in some bacteria, many proto-
zoa, viruses, ﬁlamentous fungi and in all metazoans, including
plants, but thus far has not been deﬁnitively documented in yeast.
O-GlcNAcylation is distinguished from ‘‘classical” glycosylation in
the following respects: (1) It is nearly exclusively on cytoplasmic
and nuclear proteins, compared to the extracellular and luminal
localization for most other protein-bound glycosyl moieties. (2)
O-GlcNAc is generally not modiﬁed or elongated to more complex
structures. (3) Like phosphorylation, O-GlcNAcylation occurs at
substoichiometric amounts and rapidly cycles on and off polypep-
tides at different rates and at speciﬁc sites in response to different
physiological stimuli, such as hormones, growth factors, and mito-
gens [3–6] (more in review [7]).
OGT and OGA are the paired enzymes responsible for the addi-
tion and removal of O-GlcNAc, respectively. Although O-GlcNAcy-
lation has many properties similar to phosphorylation, the two
PTMs are regulated very differently. Phosphorylation is determined
by hundreds of speciﬁc kinases, each encoded by a distinct gene. Inpean Biochemical Societies.
Fig. 1. Hexosamine biosynthetic pathway (HBP) and O-GlcNAcylation. In addition
to glycolysis and glycogen synthesis, 2–5% of cellular glucose is processed through
HBP. GFAT mediated conversion of fructose-6-phosphate to glucosamine-6-phos-
phate is the rate-limiting step of HBP. The presence of elevated FFA has been linked
to inhibition of glycolysis and elevated glucose ﬂux through HBP. UDP-GlcNAc is the
end product of the HBP. OGT catalyzes the transfer of O-GlcNAc from UDP-GlcNAc
onto the hydroxyl moiety of serine or threonine residues, while OGA catalyzes the
removal of the sugar. Addition of glutamine or glucosamine elevates global
O-GlcNAcylation. OGT = uridine diphospho-N-acetylglucosamine:polypeptide b-N-
acetylglucosaminyl transferase, OGA = b-D-N-acetylglucosaminidase, UDP-Glc-
NAc = uridine diphospho-N-acetylglucosamine, GFAT = L-glutamine: D-fructose-6-
phosphate aminotransferase, and FFA = free fatty acid.
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served gene in animals (two alleles of OGT in plants [8]), which
contains their catalytic centers and numerous protein–protein
interaction domains [9–11]. Like RNA polymerase II (RNAP II),
phosphatases [12] and other enzymes, OGT’s and OGA’s substrate
speciﬁcity is mostly determined by its transient interactions with
many binding partners to form various substrate speciﬁc holoen-
zymes [13,14]. The OGT catalytic subunit also has pronounced
speciﬁcity to peptide sequence around the attachment site, but
no absolute consensus sequence exists. In addition, OGT’s enzy-
matic activity is highly responsive to the concentration of uridine
diphospho-N-acetylglucosamine (UDP-GlcNAc), the donor sub-
strate for O-GlcNAcylation [15].
OGT is found in many organisms, from Caenorhabditis elegans,
Drosophila, plants to human, and shares very high homology among
species [7]. The Ogt gene resides on the X chromosome near the
centromere. Knock-out studies have shown that Ogt is required
for the viability of embryonic stem (ES) cells and other cells, even
in cell culture [16]. Tissue targeted Ogtmutations in mice and sev-
eral cell lines, such as T-lymphocytes, neuronal cells, and ﬁbro-
blasts, using the Cre-loxP recombination system, demonstrated
that loss of O-GlcNAcylation results in concomitant loss of cell
function and eventually cell death [16]. In contrast to plants and
mammals, in C. elegans, Ogt knockout, while producing profound
metabolic changes, such as insulin resistance and abnormal metab-
olism, does not cause the death of the worm [17]. This and a recent
genetic study in C. elegans support a role for O-GlcNAcylation in
regulating cellular signaling, insulin resistance, longevity, stress
as well as immunity [18]. For humans, there are at least three tran-
script isoforms of OGT: 110 kilodalton (kDa) (p110), 78 kDa (p78)
and 103 kDa (p103), with variation from 2.5 to 13.5 tetratricopep-
tide repeats (TPRs). The catalytic p110 subunit can form either a
homodimer or heterotrimer with p78 in the cytoplasm and nucleus
depending on cell type, while p103 is localized to the mitochondria
[7,9,19]. OGT’s catalytic subunit is composed of two separate do-
mains. Its N-terminus contains TPRs, which mediate protein–pro-
tein interactions, thus functioning in OGT substrate recognition
and multimerization. The C-terminus of p110 has the catalytic do-
main, possessing glycosyltransferase activity [20,21]. Structural
analysis of the N-terminal TPR domain shows a right-handed
superhelix of about 100 Å long and 35 Å wide, which likely pro-
vides for substrate binding on its concave surface [22]. The crystal
structure of Xanthomonas campestris OGT, a bacterial orthologue of
human OGT, shows that OGT has a conserved UDP-GlcNAc binding
pocket. This structure also shows that the last few TPR repeats are,
closely associated with the C-terminal active site, forming an elon-
gated, continuous groove from the donor substrate binding site to
the end of the TPR superhelix [23,24]. Molecular modeling of the
bacterial structure and the mammalian TPR repeat structure
strongly supports the structure proposed for the mammalian
OGT [13–15].
OGA was initially identiﬁed as hexosaminidase C, with b-linked
GlcNAc substrate speciﬁcity, neutral pH optima, and mainly a cyto-
solic localization, unlike lysosomal hexosaminidases [25–27].
Strikingly, Oga knockouts in C. elegans showed similar metabolic
defects as the Ogt knockouts, such as elevated stores of glycogen,
and decreased lipid storage. This ﬁnding suggests that O-GlcNAc
cycling rates and not its absolute stoichiometry may be important
in its regulation of cellular metabolism. Human OGA (hOGA) is a
92 kDa bifunctional protein, its N-terminus contains O-GlcNAc
hydrolase activity, and its C-terminus bears a putative histone ace-
tyltransferase (HAT) domain. Caspase-3, a cysteine-aspartic prote-
ase that serves as the ‘‘executioner protease” in apoptosis, cleaves
these two domains during apoptosis without affecting the O-Glc-
NAc hydrolase catalytic activity [28,29]. hOGA catalyzes O-GlcNAc
hydrolysis using a substrate-assisted mechanism, which requiresthe involvement of the 2-acetamido group of GlcNAc as the nucle-
ophile [30]. Similar catalytic mechanisms were also conﬁrmed on
bacterial OGA orthologues from Clostridium perfringens NagJ and
Bacteroides thetaiotaomicron BtGH84 [31,32].
2. O-GlcNAcylation is a nutrient and stress sensor
As stated above, UDP-GlcNAc, the immediate donor substrate
for O-GlcNAcylation, is a terminal product of the hexosamine bio-
synthetic pathway (HBP) (Fig. 1). This sugar nucleotide is second
only to adenosine triphosphate (ATP) in abundance for high-energy
small molecules in cells. When HBP ﬂux changes, UDP-GlcNAc lev-
els also change rapidly, altering the extent of O-GlcNAcylation of
many proteins. HBP ﬂux and UDP-GlcNAc availability are affected
directly by many different nutrients, such as glucose, fatty acids,
and amino acids. Exogenously added glucosamine is efﬁciently
‘salvaged’ by cells, and small amounts can dramatically increase
UDP-GlcNAc pools in cells. When glucose enters cells, besides
being used for glycogen synthesis or glycolysis, 2–5% is converted
to UDP-GlcNAc [33]. Free fatty acids can increase HBP ﬂux by
inhibiting glycolysis, resulting in elevated fructose-6-phosphate
levels. Acetyl-CoA, produced by fatty acid metabolism, serves as
the donor for the acetylation of glucosamine in the formation of
UDP-GlcNAc. L-glutamine: D-fructose-6-phosphate aminotransfer-
ase (GFAT) is the key rate-limiting enzyme of the HBP. GFAT con-
verts fructose-6-phosphate to glucosamine-6-phosphate, using
glutamine as the nitrogen donor. GFAT is bypassed by glucosamine,
which enters directly into the HBP by being phosphorylated to
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tin, a hormone that regulates nutrient uptake, have elevated GFAT
activity and increased UDP-GlcNAc levels in muscle. UDP-GlcNAc
levels are increased in tissues by hyperglycemia, hyperlipidemia,
as well as by glucosamine [35,36]. The substrate speciﬁcity of
OGT, as well as its enzymatic activity are regulated by different lev-
els of UDP-GlcNAc [15]. In hyperglycemia, elevated HBP ﬂux cause
increased O-GlcNAcylation on speciﬁc insulin signaling molecules,
such as Akt, insulin receptor substrate 1 (IRS1), and others, to neg-
atively regulate the insulin pathway. Excessive O-GlcNAcylation of
insulin signaling molecules results in less insulin-stimulated glu-
cose transport [34]. Hyperglycemia and hyperlipidemia also affect
transcription by increasing the O-GlcNAcylation of transcription
factors, such as Sp1. For example, the saturated fatty acid, palmi-
tate, which causes increased HBP ﬂux, increases Spl’s DNA binding
activity, as well as its transcription activity by elevating its O-Glc-
NAcylation state [37].
O-GlcNAcylation is also a sensor of cellular stress. Multiple
forms of stress increase glucose uptake and thus HBP ﬂux and con-
comitantly increase UDP-GlcNAc concentrations, leading to rapidly
increased global O-GlcNAcylation. Many different stresses, such as
oxidative, osmotic, ultraviolet light, ethanol, and heat shock induce
rapid and global increased O-GlcNAcylation. Elevated O-GlcNAcy-
lation induced by thermal stress occurs rapidly and returns back
to basal levels after removing the stress. Thermal stress increases
OGT’s enzymatic activity but does not increase its expression. In
contrast, OGT expression is increased by ethanol treatment or by
osmotic stress. Ogt knockout through Cre-LoxP in mouse embry-
onic ﬁbroblasts cells or knockdown of Ogt by RNA interference
(RNAi) in mouse neuroblastoma cells (Neuro-2a) both decreased
thermotolerance. Artiﬁcally increasing cellular O-GlcNAc levels
by pharmacologically inhibiting OGA activity, using O-(2-acetam-
ido-2-deoxy-D-glucopyranosylidene)amino-N-phenylcarbamate
(PUGNAc), resulted in increased thermotolerance. This protective
effect of O-GlcNAcylation on thermal stress is partially explained
by elevating heat shock protein 70 (Hsp70) and Hsp40 expression
[38], chaperone complex of these two proteins is well known as a
heat protector in mammalian cells [39]. Hsp70, which protects
cells from stress, is also an endogenous O-GlcNAc binding lectin
[40].
Paradoxically, despite lower UDP-GlcNAc and ATP levels, global
O-GlcNAcylation is strikingly increased when neuronal cells are
deprived of glucose. When Neuro-2a cells are deprived of glucose,
increased OGT mRNA and protein expression are observed. In-
creased targeting of OGT to a population of substrate proteins,
rather than an increase in its catalytic activity was found. This in-
crease of OGT towards glucose-deprivation dependent population
of proteins in Neuro-2a cells was dependent upon AMP-activated
protein kinase (AMPK) and mitogen activated protein kinase
(MAPK)/p38 [13]. However, in human hepatocellular carcinoma
cells (HepG2), glucose-deprivation dependent elevation of O-Glc-
NAcylation results mainly from increased OGT mRNA and protein
expression, as well as decreased OGA expression, but does not ap-
pear to be dependent upon speciﬁc kinases [41,42]. Glucose- depri-
vation increases O-GlcNAcylation in human non-small cell lung
carcinoma A549 cells, by yet another mechanism. In A549 cancer
cells, glucose-deprivation results in increased HBP ﬂux, as well as
increased UDP-GlcNAc levels. The source of glucose driving the in-
creased HBP ﬂux is from increased glycogen phosphorylase activ-
ity, the rate-limiting step in mobilizing glycogen. In A549 cancer
cells glucose-deprivation also results in increased GFAT activity.
In addition, glucose-deprivation in A549 cells results in higher
OGT enzymatic activity and lower enzymatic activity for OGA
without changing OGT and OGA expression levels [43]. The differ-
ent mechanisms elevating O-GlcNAcylation in response to glucose-
deprivation may result from the distinct difference in regulatingenergy metabolism among these cell types. Thus, there are com-
plex and intimate relationships between nutrient status, stress
and O-GlcNAcylation. O-GlcNAcylation not only responds to nutri-
ent status and stress, but also regulates cell’s response to variations
in nutrients and stress.
3. Detection and site mapping of O-GlcNAc
O-GlcNAcylation can be detected by using pan-speciﬁc anti-O-
GlcNAc antibodies (CTD 110.6, RL2, HGAC 85) or lectins (succiny-
lated Wheat-Germ Agglutinin, sWGA). CTD 110.6 is an IgM
monoclonal antibody produced using a chemically synthesised O-
GlcNAcylated peptide based upon a single repeat of the RNAP II
carboxyl terminal domain (CTD) motif as the antigen [34]. RL2 is
an IgG monoclonal antibody produced using nuclear pore protein
complex fractions as the antigen. HGAC 85 is an IgG monoclonal
antibody made against streptococcal group A polysaccharide,
which recognizes O-GlcNAc [44]. All of these antibodies favor the
detection of highly abundant O-GlcNAcylated proteins. While
mostly recognizing O-GlcNAc, these antibodies differ in their
dependency upon peptide structure and bind different subsets of
O-GlcNAcylated proteins [45,46]. Recently, several O-GlcNAc pep-
tide speciﬁc monoclonal antibodies have been described, which
may prove valuable in further deﬁning the biological roles of
O-GlcNAcylation [47]. The lectin, sWGA, is able to recognize any
terminal GlcNAc, including those on N-glycans, O-glycans or
O-GlcNAc, and has a preference for clustered O-GlcNAcylation.
Regardless of which probe is used, additional controls, such as inhi-
bition of binding by excess GlcNAc, prior treatment with hexosa-
minidase to remove terminal GlcNAc in N-glycans, or ‘capping’
the epitope with galactosyltransferase should be used [34] to val-
idate speciﬁcity.
As with any PTM, mapping the attachment site(s) is a prere-
quisite toward understanding the modiﬁcation’s biological func-
tions. Site mapping O-GlcNAcylation is very difﬁcult due to its
special characteristics: (1) O-GlcNAcylation usually has low stoi-
chiometry at each site on proteins. For example, stoichiometry of
O-GlcNAcylated a-crystallin, a structural protein in the eye lens,
is less than 2% [48,49]. (2) In mass spectrometry (MS), the pres-
ence of even a small proportion of unmodiﬁed peptide ions se-
verely suppresses ionization of O-GlcNAcylated peptides. (3)
The b-linkage between O-GlcNAc moiety and Ser(Thr) is labile.
Upon fragmentation by standard collision induced dissociation
(CID) or collision activated dissociation (CAD), the glycosidic
bond breaks ﬁrst, resulting in poor fragmentation of the glyco-
peptide and loss of any site information. With the development
of sample enrichment methods and new mass spectrometry frag-
mentation methods, such as electron capture dissociation (ECD)
and electron transfer dissociation (ETD), it is now possible to
map and quantify both O-GlcNAc and phosphosites simulta-
neously in complicated samples using relatively limited amounts
of protein [50].3.1. Early approaches to map O-GlcNAc sites
In early studies, mapping O-GlcNAc sites was a tedious and
time-consuming process, often taking nearly one-year. In these
early studies, O-GlcNAc site mapping was achieved by ﬁrst tagging
the O-GlcNAc protein or peptide by enzymatically attaching a [3H]-
galactose, using bovine milk b-1,4-galactosyltransferse (GalT1) [1].
Multiple rounds of reverse phase high performance liquid chroma-
tography (RP-HPLC) of tryptic peptides were then used to obtain
pure radiolabeled glycopeptides. Automated Edman degrada-
tion was used to sequence the peptide, and followed by manual Ed-
man degradation to determine which residue contained the
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way, such as Thr48 and Thr431 on neuroﬁlament M (NF-M), Thr21
and Ser27 on NF-L [52,53]. Sites on estrogen receptor (ER), as well
as synapsin I were also mapped via this method [54–56]. However,
this method had many problems: (1) It contains too many steps
and requires expensive radioactive sugar nucleotide. (2) Many
rounds of HPLC and Edman degradation are needed to deﬁnitively
identify the major O-GlcNAc sites on a single protein. (3) The over-
all procedure is time consuming and difﬁcult. (4) Large amounts of
starting sample are required. For example, in order to map O-Glc-
NAc sites, at least 10 pmol of pure, radiolabeled glycopeptide is re-
quired. Due to sample loss, low stoichiometry of O-GlcNAcylation
as well as limits in detecting [3H]-galactose, typically nanomole
to even micromole amounts of starting protein are often required.
3.2. Mapping O-GlcNAc sites on recombinant or in vitro expressed
proteins
It often is difﬁcult to obtain enough of a low abundance endog-
enous regulatory protein, such as a transcription factor, to map O-
GlcNAc sites, even with the best methods currently available. Three
approaches have proven useful, at least as a starting point: (1) For
low abundance proteins where DNA is available, the protein can be
transcribed and translated in a reticulocyte lysate system, which
efﬁciently O-GlcNAcylates nascent proteins [57]. Lectin afﬁnity
chromatography on sWGA is then used to detect O-GlcNAcylation
[56,58,59]. (2) Overexpression of the protein in Escherichia coli,
which does not O-GlcNAcylate proteins, allows for production of
a polypeptide substrate, that can be O-GlcNAcylated in vitro using
recombinant OGT later. This approach allows for site mapping,
which can readily be conﬁrmed in vivo by site-directed mutagene-
sis, combined with anti-O-GlcNAcWestern blotting. (3) Fairly large
quantities of in vivo O-GlcNAcylated proteins can be obtained by
overexpressing afﬁnity-tagged proteins (eg. His, Flag, or GST). This
can be done in either insect cells via baculovirus infection
[54,56,60–62] or transfection in HEK293 mammalian cells [63–
65]. Thus far, sites mapped to be O-GlcNAcylated in these model
systems are also found existing in other cell types. However, puta-
tive O-GlcNAc sites need to be directly conﬁrmed in the cell type
studied, usually via site-directed mutagenesis and/or by MS.
3.3. O-GlcNAc enrichment methods
Using large-scale protein preparations, while mitigating the low
stoichiometry of O-GlcNAc, increases the risk of ion-suppression
by non-glycosylated peptides. Therefore, it is almost always neces-
sary to purify O-GlcNAcylated proteins or peptides away from the
unmodiﬁed peptides.
3.3.1. Immunoafﬁnity/lectin based enrichment methods
The simplest O-GlcNAc enrichment approach is to purify O-Glc-
NAcylated proteins using immunoafﬁnity or lectin chromatogra-
phy. O-GlcNAcylated proteins from cell lysates are efﬁciently
enriched by both anti-O-GlcNAc antibody afﬁnity chromatography
or by sWGA afﬁnity chromatography [66–68]. However, both
methods favor enrichment of high abundance proteins (e.g. nuclear
pore proteins) or those with multiple clustered O-GlcNAc residues.
Low abundance proteins with single or widely separated O-GlcNAc
sites are difﬁcult to purify using these tools, because their binding
to the afﬁnity solid support is often competed by more abundant or
higher afﬁnity O-GlcNAcylated proteins.
3.3.2. Metabolic in vivo tagging of O-GlcNAc for enrichment (tagging-
via-substrate (TAS))
TAS based enrichment method takes advantage of the fact that
the cellular machinery will take up and use N-azidoacetylglucos-amine (GlcNAz) as an alternative substrate to GlcNAc. In order to
facilitate uptake by living cells, GlcNAz is peracetylated. Upon up-
take, the peracetylated GlcNAz is rapidly deacetylated by intracel-
lular esterases. GlcNAz enters the HBP just like glucosamine, but at
lower efﬁciency, and is converted into UDP-N-azidoacetylglucos-
amine (UDP-GlcNAz). UDP-GlcNAz is utilized by OGT, and O-Glc-
NAz is attached to Ser(Thr) sites. The GlcNAz on proteins enables
conjugation via Staudinger ligation to enrichment tags, such as a
biotinylated phosphine [69]. After ligation, the labeled sample
can be selectively puriﬁed using avidin/streptavidin beads. By
using TAS, 199 putative O-GlcNAcylated proteins were identiﬁed
in Hela cells (human cervical cancer cell line) through nano-
HPLC-MS/MS [70]. The high afﬁnity between biotin and avidin/
streptavidin allows for a high degree of enrichment by permitting
stringent washes to eliminate nonspeciﬁcally bound materials,
therefore minimizing contamination from unmodiﬁed peptides,
decreasing ion suppression effect. The major disadvantage of this
approach is the poor utilization efﬁciency of GlcNAz by cells. All
of the enzymes in the cellular machinery use their natural sub-
strates much more efﬁciently. In addition, high concentrations of
endogenous UDP-GlcNAc that are present in most cells effectively
competes for utilization of exogenous UDP-GlcNAz. Furthermore,
the lack of sensitivity is further exacerbated by the often low stoi-
chiometry of O-GlcNAcylation. Unfortunately, lowering endoge-
nous UDP-GlcNAc levels to increase efﬁciency of GlcNAz
incorporation will more or less affect the biological process of
interest. Nonetheless, the TAS approach is useful for studying O-
GlcNAcylation on abundant proteins and perhaps on those where
the saccharide is most rapidly cycling.
3.3.3. b-Elimination followed by Michael Addition-based enrichment
The O-b-GlcNAc glycosidic linkage is much more alkali labile
than O-a-GalNAc or O-phosphate. Since O-GlcNAc is very sensitive
to b-elimination by alkali, and is very labile in the gas phase upon
CID fragmentation, early site mapping studies used mild b-elimina-
tion of O-GlcNAc peptides and the resulting loss of water at the
Ser(Thr) attachment site (18m/z loss) to map sites [71]. Later, this
method was improved by using Michael Addition chemistry to at-
tach dithiothreitol (DTT) to the b-eliminated O-GlcNAc sites (m/z
increase of 136). This method is called, b-elimination followed by
Michael Addition with DTT (BEMAD) [66]. BEMAD provides several
advantages: (1) DTT allows for afﬁnity enrichment of modiﬁed
peptides using thiol-afﬁnity chromatography. (2) The attached
DTT moiety is stable under standard MS/MS conditions, such as
CID, and modiﬁed peptides fragment normally. (3) Deuterium
containing DTT is readily available allowing for comparative
semi-quantitative mass spectrometry [66,72,73]. The biggest
disadvantage of the BEMAD method for site mapping is that it is
indirect. In theory, alkali-induced elimination of any moiety at a
Ser(Thr) residue could result in a false positive assignment as an
O-GlcNAc site. Therefore, the use of BEMAD for site mapping
requires many careful controls [72,74,75], and conﬁrmation by
independent methods.
3.3.4. Chemoenzymatic enrichment of O-GlcNAc peptides
Most recently, chemoenzymatic approaches have been used to
tag and enrich O-GlcNAcylated peptides. A commercially available
kit (‘‘Click iT” kit, Invitrogen) has simpliﬁed the use of this ap-
proach. The method uses a genetically engineered (Y289L muta-
tion) GalT that has a larger donor-substrate binding pocket. The
mutant GalT can efﬁciently transfer N-azidoacetylgalactosamine
(GalNAz) to the O-GlcNAc moiety [76]. Biotin is then quantitatively
attached to GalNAz via click chemistry using a copper catalyst [77].
The labeled proteins/peptides can then be enriched through avidin/
streptavidin afﬁnity chromatography. Even though this tagging
and enrichment method greatly enriches the O-GlcNAcylated
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mapping by direct CID/CAD MS/MS for the following reasons: (1)
The large mass of the tag attached to the O-GlcNAc results in even
more severe ion suppression compared with non-enriched O-Glc-
NAcylated peptides. (2) The biotin moiety fragments excessively
during MS/MS, complicating interpretation of the spectra. (3) The
saccharide moiety bearing the GalNAz-biotin is still very labile
during MS/MS fragmentation, preventing direct site mapping.
The combined use of BEMAD and the chemoenzymatic enrich-
ment does allow for direct site mapping and the high speciﬁcity
of the enrichment gives a much higher conﬁdence in the validity
of sites identiﬁed. The combined approaches have been used to
map O-GlcNAc sites on vimentin and calcium/calmodulin-depen-
dent kinase IV (CaMKIV) [65,67]. A complex mixture of human
erythrocyte proteins was also analysed using this chemoenzymatic
enrichment followed by BEMAD, resulting in the identiﬁcation of
35 O-GlcNAc sites [73]. A similar enrichment method that alterna-
tively uses an UDP-ketogalactose and hydrazide coupling to biotin
also works well, and has been used in cell lysates and brain tissue
[78,79].
3.3.5. Photocleavable biotin (PC-biotin) based enrichment of O-GlcNAc
peptides
A major problem with enriching O-GlcNAc using biotin-avidin
based afﬁnity methods is the difﬁculty of getting quantitative
recovery of the bound glycopeptides. Thus, building upon Olejnik’s
report of a PC-biotin reagent [80], a PC-biotin-alkyne reagent suit-
able for use in O-GlcNAc site mapping was developed [50]. The
same chemoenzymatic attachment method (described above) is
used, but the tagged glycopeptides are quantitatively released
from the avidin/streptavidin columns by a cleavage reaction cata-
lyzed by ultraviolet light (365 nm). A major advantage of this
method, in addition to its efﬁciency, is that the released peptides
now carry a basic aminomethyltriazolyl acetylgalactosamine
group, which results in a 3+ or higher charge state for the tryptic
O-GlcNAc peptides. The charged moiety remaining after ultraviolet
light cleavage not only facilitates ETD MS, but also produces diag-
nostic fragment ions (m/z of 300.2 and 503.1) allowing detection of
O-GlcNAc peptides in complex mixtures by standard CID/CAD MS
[50].
3.4. Advances in MS that facilitate analyses of O-GlcNAc
The enrichment methods, described above, have partially
solved the analysis problems associated with the low stoichiome-
try and the ion suppression by unmodiﬁed peptides. In addition,
increased sensitivity of modern mass spectrometers further aid
in O-GlcNac site mapping.
3.4.1. CID/CAD
As noted above, O-GlcNAc attachment to Ser(Thr) is labile. In
CID/CAD, the energy required to break the O-GlcNAc linkage is
much lower than that required to break the peptide bond. CID/
CAD almost always results in a neutral loss of the saccharide,
which can indicate the existence of O-GlcNAcylation on the pep-
tide without any site information [81–83]. In addition, due to the
loss of kinetic energy associated with the neutral loss of the sac-
charide, CID/CAD is generally very poor at producing enough pep-
tide fragmentation of the O-GlcNAc peptide for sequencing.
However, in ion-trap mass spectrometers it is possible to perform
an MS3 CID/CAD and obtain good quality peptide sequence, but
only after the sugar is lost. In contrast, DTT attached by the BEMAD
procedure, is not lost during CID/CAD and the DTT-peptides frag-
ment as well as unmodiﬁed peptides. A combination of BEMAD
and CID/CAD, has been used to map sites on synapsin I, nuclear
pore complex proteins, actin, myosin, and IRS-1 [84,85].3.4.2. ECD/ETD
ECD uses low energy electrons to react with peptide cations in
the magnetic ﬁeld of a Fourier transform ion cyclotron resonance
(FT-ICR) mass spectrometer [86]. Unlike CID/CAD mass spectrome-
try, the O-GlcNAc linkage is not broken by ECD of peptide ions [68].
However, the high cost and high level of expertise required to
operate and maintain FT-ICR mass spectrometers limits their wide-
spread use. Recently, an ionization method similar to ECD, ETD has
been developed which works well in lower cost ion trap mass spec-
trometers [87,88]. During ETD an electron is transferred in the gas
phase from a radical anion to a protonated peptide to induce cleav-
age of the Ca–N bond. Like ECD, ETD preserves the O-GlcNAc and
other peptide modiﬁcations, while efﬁciently fragmenting the pep-
tide. The development of ETD is a breakthrough in the detection
and analysis of O-GlcNAcylation. ETD mass spectrometry has re-
cently been used to map O-GlcNAc on paxillin, a focal adhesion
adaptor protein, IRS-1 and Forkhead box O1 (FoxO1), and peroxi-
some proliferator activated receptor c coactivator-1a (PGC-1a)
[14,64,89,90]. By combining ETD with sWGA chromatography
enrichment, more than 50 previously unknown O-GlcNAc sites
on murine postsynaptic density proteins were mapped [91]. Che-
moenzymatic enrichment using a PC-biotin tag, combined with
ETD MS/MS, enabled the mapping of over 140 O-GlcNAc sites on
proteins involved in the regulation of cell division [92].
3.5. Quantitative analysis of O-GlcNAc site occupancy
3.5.1. Stable isotope labeling with amino acids in cell culture (SILAC)
In order to quantitatively compare O-GlcNAc levels on different
proteins or at different sites, SILAC [93,94], when combined with
the MS methods discussed above, has proven to be a method of
choice. SILAC was used to test quantitative O-GlcNAcylation
changes in COS7 cells after only a single kinase, glycogen synthase
kinase-3 (GSK-3), was inhibited [92]. Major disadvantages of SILAC
include the high cost of isotope containing amino acids, and that
the metabolic incorporation of the labeled amino acids requires
living samples, either in culture or at the whole organism level.
3.5.2. In vitro methods for isotopically labeling O-GlcNAc peptides
Recently, two similar in vitromethods have been used for quan-
titative analysis of O-GlcNAcylation by isotopically labeling pep-
tides with different tags [73,95]. One approach is ‘‘tandem mass
tags” (TMT) and the other is ‘‘isobaric tags for relative and absolute
quantiﬁcation” (iTRAQ) [96,97]. Peptides are labeled with different
tags, which upon tandem mass spectrometry are cleaved into dif-
ferent m/z reporter ions. Each tag introduces a unique mass shift
for the labeled peptides. The advantage of these tags is that they
allow for multiplexing, and peptides obtained from tissues or other
sources can be efﬁciently labeled in vitro. A similar peptide labeling
method makes use of reductive amination to incorporate stable
isotopes into N-terminal amines and e-amino groups of lysine res-
idues [98]. Using this approach, a quantitative isotopic and chemo-
enzymatic tagging (QUIC-tag) method was developed for O-GlcNAc
analysis. In this method, O-GlcNAcylated peptides are ﬁrst en-
riched by the modiﬁed chemoenzymatic enrichment method (dis-
cussed above), and then the biotin labeled O-GlcNAcylated
peptides are dimethylly isotopically labeled. By using the QUIC-
tag approach, many quantitative O-GlcNAc changes on proteins
after inhibition of O-GlcNAcase, as well as after different stimula-
tions of the brain were identiﬁed [99].
3.5.3. b-Elimination Michael Addition with density tagged DTT
Using chemoenzymatic enrichment (as above) combined with
BEMAD, but using deuterated DTT (DTT-[3D]6) for one sample
and light DTT for the other samples, allows for direct comparison
of O-GlcNAc site occupancy, as long as the necessary controls are
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compare O-GlcNAc site occupancy ratio between sites on proteins
from erythrocytes between normal and diabetic patients [73]. The
advantage of this approach is that it can be performed on inexpen-
sive ion trap mass spectrometers using CID/CAD tandem mass
spectrometry. The disadvantage (as discussed above) is that detec-
tion of O-GlcNAc is indirect.
With the development of these new methods, the pace of iden-
tiﬁcation and site mapping of O-GlcNAcylated proteins is rapidly
increasing. In fact, the total O-GlcNAc sites mapped within the past
two years exceeds that known during the past 20 years [1]. Fig. 2
summarizes the current approaches available for identiﬁcation
and site-mapping O-GlcNAc on proteins.
4. Extensive crosstalk exists between phosphorylation and
O-GlcNAcylation
O-GlcNAcylation occurs on Ser(Thr) side chains of proteins at
sites that may also be phosphorylated. Thus far, virtually everyFig. 2. O-GlcNAc enrichment and site mapping methods. O-GlcNAc sites can be
mapped by: (A) directly analysing the puriﬁed target protein, cell extracts,
fractionated lysates, or samples enriched for O-GlcNAc by immuno afﬁnity
chromatography by ETD MS. (B) Enriching for O-GlcNAc modiﬁed peptides, derived
from the puriﬁed target protein, total cell lysates or fractionated lysates, by the PC-
biotin method and subsequently analysing by ETD MS. (C) Modifying O-GlcNAc
sites of enriched O-GlcNAc modiﬁed peptides using BEMAD and analysing by CAD/
CID MS. (D) In culture labeling the proteins with GlcNAz and processing through
PC-biotin or biotin enrichment methods. Various quantitative peptide tags may be
introduced at speciﬁed steps to allow for comparative analysis of multiple sets of
samples. PC-biotin = photocleavable biotin, BEMAD = b-elimination followed by
Michael addition with DTT, GalNAz = N-acetyl-azido-galactose, ETD MS/MS = elec-
tron transfer dissociation mass spectrometry, CAD/CID MS/MS = collisionally acti-
vated dissociation/collision induced dissociation mass spectrometry,
iTRAQ = isobaric tags for relative and absolute quantitation, SILAC = stable isotope
labeling with amino acid in cell culture, and DTT = dithiothreitol, QUIC-tag = quan-
titative isotopic and chemicoenzymatic tag.O-GlcNAcylated protein can also be phosphorylated [100]. After
several O-GlcNAc sites were mapped and discovered to also be
phosphorylation sites, a ‘‘Yin–Yang” model was proposed for the
relationship between O-GlcNAcylation and phosphorylation
[101]. This model suggested that O-GlcNAcylation is reciprocal to
phosphorylation with mutually exclusive occupancy at the same
site on a polypeptide. While largely correct for many proteins,
the ‘‘Yin–Yang” model is an oversimpliﬁcation. Now hundreds of
O-GlcNAc sites have been mapped, and some cellular stimuli were
shown to increase both modiﬁcations, it is clear that the interplay
between O-GlcNAcylation and phosphorylation is both complex
and very extensive.
4.1. Global interactions between O-GlcNAcylation and phosphorylation
4.1.1. Global interactions between O-GlcNAcylation and
phosphorylation may be antagonistic or synergistic
Reciprocal relationships between O-GlcNAcylation and phos-
phorylation have indeed been found in several global analyses.
Global O-GlcNAc level changes were detected after using various
kinase activators and inhibitors. For example, activation of protein
kinase A (PKA) or protein kinase C decreased global O-GlcNAcyla-
tion and inhibitors of these kinases increased global O-GlcNAcyla-
tion [102]. Okadaic acid (OA), a broad-spectrum phosphatase
inhibitor, has been used to explore the global interplay between
O-GlcNAcylation and phosphorylation. Indeed, in some cells,
short-term OA treatment decreases O-GlcNAcylation [103]. How-
ever, since OA also induces a stress response that increases O-Glc-
NAcylation of many proteins by other mechanisms, these types of
global treatments are not very informative.
In hippocampal neuronal synapses, pharmacological elevation
of O-GlcNAc in vivo, concomitantly increases phosphorylation of
synapsin I/II at serine9 (PKA site), serine62/67 (Erk1/2 site), and ser-
ine603 (CaMK II site) [104]. These and other studies indicate that
the nature and direction of the crosstalk between these two post-
translational modiﬁcations depends upon not only the protein but
also the speciﬁc modiﬁcation site.
4.1.2. Proteomic studies of global interactions between
O-GlcNAcylation and phosphorylation
Chemoenzymatic enrichment methods and advances in mass
spectrometry have allowed global comparisons of O-GlcNAcylation
and phosphorylation at the individual site level. In studies to deter-
mine the affects of inhibiting GSK-3 on O-GlcNAcylation, of the 45
identiﬁed O-GlcNAcylated proteins, at least 10 proteins (mostly
cytoskeletal proteins) had increased O-GlcNAcylation, while 19
other proteins (mostly RNA binding proteins) had decreased O-Glc-
NAcylation [67]. A recent study examined the affects of globally
increasing O-GlcNAcylation, by inhibiting OGA, on the quantitative
site occupancy of phosphate at over 700 phosphorylation sites in
non-stimulated NIH3T3 cells [105]. Forty eight percentage of the
phospho-sites were not actively cycling in these non-stimulated
cells, as judged by insensitivity to OA. However, of the remaining
actively cycling phospho-sites nearly all had their level of phos-
phorylation affected by altered O-GlcNAcylation. Elevated O-Glc-
NAcylation signiﬁcantly reduced phosphorylation at about 280
sites and signiﬁcantly increased phosphorylation at 149 sites.
These studies revealed the surprisingly extensive level of crosstalk
between these two most abundant PTMs. This extensive crosstalk
not only results from competition at the same or proximal attach-
ment sites, but also it is now clear that phosphorylation regulates
OGT activity. In addition, O-GlcNAc is being found to regulate an
increasing number of kinases [65,106–108].
Overexpression of OGT causes defective cytokinesis increasing
polyploidy in cells, a feature common to many cancer cells [109].
In order to understand the molecular basis for OGT’s induction of
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analysis, using chemoenzymatic enrichment with PC-biotin and a
combination of CID and ETD MS/MS was carried out on spindle/
midbody preparations isolated from HeLa cells either overexpress-
ing GFP (control) or OGT (experimental) [92]. A comparable num-
ber of phosphorylation and O-GlcNAcylation sites were mapped
(350 phosphorylation sites on 190 proteins vs. 141 O-GlcNAcylated
peptides on 64 proteins). Seventeen percentage of the phospho-
sites showed more than a 50% decrease upon a twofold over-
expression of OGT and the resulting increase in global O-GlcNAcy-
lation. Some (7%) phosphorylation sites had a more than 200%
increase in site occupancy. These changes resulted in pronounced
inhibition of the cyclin dependent kinase I signaling pathway and
alterations in polo kinase as well as aurora kinase signaling, which
partially explained the cytokinesis defects induced by OGT overex-
pression. These data clearly exemplify the importance of the inter-
play between O-GlcNAcylation and phosphorylation in cellular
signaling pathways.
4.2. Physiological signiﬁcance of the crosstalk between
O-GlcNAcylation and phosphorylation
4.2.1. Crosstalk between O-GlcNAcylation and phosphorylation at the
protein level
Hyperphosphorylation of the microtubule bundling protein, tau,
is a characteristic of Alzheimer’s disease (AD). It has also been
known for some time that tau is heavily O-GlcNAcylated in normal
brain [110]. These ﬁndings led to the proposal that defective glu-
cose metabolism in the brain results in lower O-GlcNAcylation of
brain proteins, including tau, leading to abnormally increased
hyperphosphorylation associated with AD [111]. Hyperphospho-
rylated tau forms visible tangles within neurons, and this is re-
ferred to as paired helical ﬁlamentous tau (PHF-tau). To date,
more than 30 phosphorylation sites have been mapped on PHF-
tau, and many of them have been used to produce site-speciﬁc
phosphorylation antibodies [112]. While there are more than 12
putative O-GlcNAc sites on tau, only a few sites have been mapped
and no site speciﬁc antibodies have been made [110]. Increased O-
GlcNAcylation negatively regulates tau phosphorylation at multi-
ple sites, and hyperphosphorylated tau has decreased O-GlcNAcy-
lation. Several studies have shown that decreased ﬂux through the
HBP or decreased expression of OGT result in tau hyperphosphory-
lation in animal models [113,114]. The potent OGA inhibitor, Thia-
met G (TMG), increases global O-GlcNAcylation effectively in
whole animals and crosses the blood–brain barrier [115]. TMG
treatment increased O-GlcNAcylation and decreased phosphoryla-
tion at pathologically relevant sites on tau, Thr231 and Ser396 in
PC12 cells and Ser422 in rat cortex and hippocampus [115].
Upon activation of the insulin signal cascade, phosphorylation
of AKT at Thr308 is increased. Concomitantly, phosphorylations on
IRS-1 at Ser307 and Ser632/635 are decreased. When OGT is overex-
pressed in mouse liver, increased O-GlcNAcylation of both AKT
and IRS-1 occurs, which results in decreased phosphorylation at
Thr308 of AKT and increased phosphorylation at Ser307 and Ser-
ine632/635 on IRS1. These ﬁndings support the hypothesis that the
crosstalk between O-GlcNAcylation and phosphorylation is com-
plex and is not simply a ‘‘Yin–Yang” relationship. Here the two
modiﬁcations function ‘‘synergistically” to regulate insulin signal-
ing [116].
The interaction between O-GlcNAcylation and phosphorylation
not only exists at the modiﬁcation site level, but also cycling
dynamics of O-GlcNAcylation and phosphorylation at the protein
level are differentially regulated. For example, on the transcription
factor, Sp1, O-GlcNAcylation of Sp1 peaks at 30 min post insulin
stimulation, followed by a steady decline, and reaches low levels
by 4 h. In contrast, the insulin stimulated phosphorylation onSp1 increases gradually and reaching a peak around 4 h after insu-
lin treatment [117,118].
4.2.2. Reciprocal crosstalk of O-GlcNAcylation and phosphorylation at
same site
Despite many exceptions, there are also numerous proteins,
such as c-Myc, (ER-b) and Akt [106], in which the O-GlcNAc moiety
and the phosphate residue compete for the same hydroxyl group,
as proposed in the ‘‘Yin–Yang” model. One of the best-studied
examples is the c-Myc oncogene protein. The protooncogene,
c-myc, regulates transcription of genes involved in cell prolifera-
tion, apoptosis and metabolism [119]. The major O-GlcNAcylation
site on c-Myc was mapped to Thr58, which is also a GSK-3b phos-
phorylation site within the transaction domain [61]. Frequent
mutation of this site is found in human lymphomas, demonstrating
the importance of this site in tumor progression [119]. Antibodies
speciﬁcally detecting O-GlcNAcylated Thr58, phosphorylated Thr58,
as well as Thr58-unmodiﬁed c-Myc were used to study the respec-
tive roles of each modiﬁcation. Serum starvation stops cell growth
and greatly increased Thr58 O-GlcNAcylation. In contrast, when
cells were stimulated to grow by serum addition, O-GlcNAcylation
at Thr58 very rapidly disappears and is replaced by increased Thr58
phosphorylation by GSK-3b. The proximal site, Ser62, is a priming
phosphorylation site and a substrate for MAPK. Phosphorylation
at Ser62 is necessary for Thr58 phosphorylation by GSK-3b. When
Ser62 is mutated to alanine, not only does Thr58 no longer become
phosphorylated, but also the extent of O-GlcNAcylation at Thr58 in-
creases dramatically. Lithium chloride, a GSK-3b inhibitor, also in-
creased O-GlcNAcylation at Thr58 similar to the Ser62Ala mutation
[120].
ER-b is reciprocally O-GlcNAcylated/phosphorylated at Ser16
[56,121]. Ser16 is within a region of ER-b with high Pro, Glu, Ser
and Thr (PEST) score, which is related to rapid protein degradation.
Site-directed mutagenesis comparisons between wild type ER-b to
mutants, S16A, S16E suggested that the O-GlcNAcylated ER-b was
muchmore stable, but less transcriptionally active, while the phos-
phorylated ER-b was transcriptionally more active, but rapidly de-
graded [122]. Consistent with the biological studies, NMR analysis
and molecular dynamics simulation of synthesised peptides, sug-
gested that phosphorylation in Ser16 discourages b-turn formation
at the N-terminus of the protein, resulting in a more extended
structure, while Ser16 O-GlcNAcylated peptides promoted b-turn
formation, adopting a more stable structure, which to some degree
might explain why O-GlcNAcylation on Ser16 can stabilize the pro-
tein [123].
Endothelial nitric oxide synthase (eNOS) function is also regu-
lated by reciprocal O-GlcNAcylation/phosphorylation crosstalk.
Ser1177 phosphorylation of eNOS by AKT activates the enzyme
and is important in positively regulating penile erection, and phos-
phorylation on Thr495 of eNOS acts as a negative regulator. Ser615
and Ser633phosphorylation can also activate eNOS. In diabetic rats,
excessive O-GlcNAcylation at Ser1177 prevents AKT activation of
eNOS without affecting phosphorylation at Thr495, Ser615 and
Ser633 [124], and in humans with diabetes O-GlcNAcylation of
eNOS contributes to erectile dysfunction [124].
Another example of direct reciprocity is Ij kinase b (IKKb). IKKb
is O-GlcNAcylated at Ser733 in its C-terminus, which is also an inac-
tivating phosphorylation site. The reciprocal interaction in this site
is responsible for regulating IKKb catalytic activity [108].
4.2.3. Crosstalk of O-GlcNAcylation and phosphorylation at proximal
sites
Perhaps more common than direct site competition is the inter-
play that occurs between O-GlcNAcylation and phosphorylation at
proximal sites. It should be noted that the Stoke’s radius of an
O-GlcNAc is several times larger than that of a phosphate moiety
Fig. 3. O-GlcNAc vs. O-phosphate modiﬁcation of CaMKIV. The structure of CaMKIV was obtained through the automated comparative modeling program SWISS-MODEL.
Mouse CaMKIV sequence (P08414) was analysed by the automated mode. The X-ray crystal structure of Human CaMKIV (protein data bank (PDB) code 2w4oA) was chosen as
a closest match template to create a model of CaMKIV. The PDB created through the homology-based modeling was then analysed using MacPymol to create the ﬁgure
presented above. (A) Unmodiﬁed CaMKIV model, the protein is depicted to show the secondary structure (gray) with Ser189 (green) and Thr200 (red) represented in stick
model. The boxed area was enlarged to show the modiﬁed forms: (B) O-GlcNAcylated CaMKIV model with O-GlcNAc (carbon is yellow, hydrogen is white, nitrogen is blue,
oxygen is pink, sphere model) attached to Ser189 (green, stick model) (Thr200 is red, stick model). (C) O-phosphorylated CamKIV model with phosphate (hydrogen is white,
oxygen is pink, phosphate is orange, sphere model) attached to the Thr200 (red, stick model) (Ser189 is green, stick model). (D) Space ﬁlling model of a GlcNAc residue. (E)
Space ﬁlling model of a phosphate residue. CaMKIV = calcium/calmodulin-dependent kinase IV.
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mor suppressor, p53, bears proximal O-GlcNAc (Ser149) and
phosphate (Thr155) residues. O-GlcNAcylation of Ser149 reduces
phosphorylation at Thr155, which subsequently blocks the interac-
tion between Mdm2, an E3 ubiquitin ligase, and p53, a prerequisite
for proteasomal degradation of p53. Thus, increased O-GlcNAcyla-
tion of p53 at Ser149 results in decreased p53 ubiquitination and
stabilizes the protein p53 [125]. Mutation of the Ser149 O-GlcNAc
site on p53 to alanine increases phosphorylation at Thr155. Three-
dimensional structural analysis shows that these two sites are lo-
cated on a ﬂexible loop with close proximity of only 11.58 Å, sug-
gesting that there might not be enough space for dual occupancy of
both phosphate and O-GlcNAc groups at these two sites.
A similar dynamic interplay between O-GlcNAcylation and
phosphorylation occurs in the C-terminal domain (CTD) of RNAP
II. The CTD of RNAP II is extensively phosphorylated during the
transition from the preinitiation complex to the assembly of the
elongation complex during transcription. On a subset of the RNA-
PII, the CTD contains no phosphate, but is extensively O-GlcNAcy-
lated at Thr1618 [126]. And Thr1616 and Thr1619 are both
phosphorylation sites [127]. The reciprocal crosstalk of the two
modiﬁcations on CTD was shown in vitro. OGT was completely un-
able to O-GlcNAcylate a CTD substrate that contained even a singlephosphate moiety. Likewise, the CTD kinase was unable to phos-
phorylate a CTD containing only a single O-GlcNAc, despite many
other sites being available [128].
Site mapping studies have recently revealed a similar proximal
interplay between O-GlcNAcylation and phosphorylation on CaM-
KIV, a key kinase regulating gene expression in neurons and other
cells (Fig. 3). CaMKIV is predominantly expressed in brain, T-lym-
phocytes and in the testis. It is a multifunctional calcium/calmod-
ulin-dependent Ser(Thr) kinase, that regulates downstream
protein activities according to changes in intracellular Ca2+ concen-
trations. CaMKIV is O-GlcNAcylated and phosphorylated on several
sites. Five O-GlcNAcylation sites were mapped on CaMKIV and O-
GlcNAc on Ser189, Thr57/Ser58 were evaluated for their interactions
with phosphorylation, mainly at the key regulatory phosphoryla-
tion site at Thr200. Phosphorylation at Thr200, which is the target
of CaMK kinase increases CaMKIV kinase enzymatic activity. Upon
neuronal depolarization using ionomycin to increase intracellular
Ca2+, phosphorylation at Thr200rapidly increases peaking at 2 min,
and decreasing after 5 min. In contrast, O-GlcNAcylation at Ser189
reciprocally decreased at 2 min, and returned to basal level at
around 10 min. Mutating Ser189 to alanine dramatically increases
both the phosphorylation of CaMKIV at Thr200 and its constitutive
enzymatic activity. Mutation of Thr57/Thr58 to alanine inactivates
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revealed that all three of these O-GlcNAc sites are located within
the catalytic cleft, near the ATP binding residues Lys75 and Asp185
(Fig. 3) [65].
4.2.4. Crosstalk between O-GlcNAcylation and phosphorylation at
distant sites
In addition to the reciprocal and synergistic crosstalk at same or
proximal sites of the proteins discussed above, crosstalk between
O-GlcNAcylation and phosphorylation also exists among distantly
located sites. IRS1 is an example of this case. Ser(Thr) phosphory-
lation sites on IRS1 are mostly located in the N-terminus. Phos-
phorylation on Ser307, Ser612, Ser632/635 negatively regulate insulin
signaling, while Ser302, Ser629 (human numbering) have positive
regulatory effects on insulin signaling [129]. However, the O-Glc-
NAcylation sites exist mainly in the C-terminus, such as Ser914,
Ser1009, Ser1036, Ser1041. While crosstalk between speciﬁc O-GlcNA-
cylation and speciﬁc phosphorylation among these sites is still un-
known, however, as mentioned above, global O-GlcNAcylation on
IRS1 has a negative regulation on insulin signal [116,130], there-Fig. 4. Interplay between O-GlcNAcylation and phosphorylation. (A) Single site
reciprocal interplay – one serine or threonine (ser/thr) site is modiﬁed either by O-
GlcNAc or phosphate. (B) Proximal sites reciprocal interplay – two or more
immediate or proximal neighboring Ser/Thr sites are reciprocally modiﬁed by O-
GlcNAc or O-phosphate. (C) Spatially proximal sites with reciprocal interplay – two
or more Ser/Thr sites that are distant in primary sequence are brought together
upon protein folding. GlcNAcylation and phosphorylation are reciprocally regu-
lated. (D) Distant sites with varied interplay – O-GlcNAc and phosphate modiﬁca-
tion of distant ser/thr sites occur simultaneously or reciprocally in signaling
dependent manner. S/T = serine/threonine, OGT = uridine diphospho-N-acetylglu-
cosamine:polypeptide b-N-acetylglucosaminyl transferase, G = O-GlcNAcylation,
and P = O-phosphorylation.fore on IRS1 the two PTMs are thought to be both reciprocally
and synergistically regulated.
In Fig. 4, we summarize different types of crosstalk between O-
GlcNAcylation and phosphorylation based upon known modiﬁca-
tion sites. These can reciprocally or synergistically interact with
each other on the same sites or proximal sites, as well as at distant
sites within proteins.4.3. Crosstalk between the cycling enzymes regulating
O-GlcNAcylation and phosphorylation
As discussed above, O-GlcNAcylation and phosphorylation cer-
tainly have extensive crosstalk due to competition of the modiﬁca-
tions themselves at the same or proximal sites on proteins.
However, they also inﬂuence each other by regulating the activities
or localizations of the other’s cycling enzymes. For example, OGT is
directly activated by tyrosine phosphorylation and is itself O-Glc-
NAcylated [15], and CaMKIV is directly inhibited by O-GlcNAcyla-
tion [65]. Src, a well known tyrosine kinase important to cancer,
phosphorylates OGT in vitro [130]. Upon insulin stimulation, OGT
is recruited to the plasma membrane by binding phosphatidylino-
sitol 3,4,5-triphosphate (PIP3). The insulin receptor phosphorylates
OGT on tyrosine, increasing its activity [116,130]. OGT also forms a
stable and active complex with Ser(Thr) protein phosphatase PP1b
and PP1c in rat brain [131]. Additionally, PP1 and the mitotic ki-
nase Aurora B form a complex with OGT and OGA during M phase
of the cell cycle. The Aurora B kinase inhibitor, ZM447439 disrupts
Aurora B’s localization to the midbody during cytokinesis, as well
as its co-localization with OGT. The transient complex that forms
at the midbody during cytokinesis regulates both the phosphoryla-
tion and O-GlcNAcylation of many proteins that regulate cell divi-
sion, including vimentin [6].5. How does a single catalytic polypeptide (OGT) speciﬁcally
modify more than a 1000 different proteins?
As mentioned above, there 385 known Ser(Thr) kinases in hu-
mans with each kinase functioning on its own speciﬁc substrates
and with its own regulatory signals [132]. However, in mammals
there is only one known gene for OGT and only two known in
plants. Thus, the site speciﬁcity of phosphorylation and O-GlcNA-
cylation are determined by very different mechanisms. How does
this single protein speciﬁcally modify so many different sequences
within proteins? There is precedence for this problem in biology.
For example, there is only a single gene encoding RNAP II’s cata-
lytic subunit. How then does RNAP II speciﬁcally transcribe in a
regulated way from so many different promoters? It is well-docu-
mented that RNAP II’s activity is determined by its ability to form
many transient protein complexes as holoenzymes with precise
speciﬁcity. Current data, suggests that this mechanism is also
how OGT’s speciﬁcity is determined. That is, in a living cell many
different holoenzymes, that are comprised of OGT and other poly-
peptides, form under speciﬁc conditions and the resulting OGT
complexes serve to speciﬁcally target the catalytic subunit to its
target proteins (Fig. 5). In addition, OGT also has speciﬁc sequence
preference, but an absolute consensus sequence has not been
identiﬁed.
Early work showed that adaptor or targeting proteins for OGT
bind to its TPR repeats to target the enzyme to transcription com-
plexes and other targets [133]. Many transcription factors, such as
Sp1, c-myc, are O-GlcNAcylated [61,134]. O-GlcNAcylation of Sp1
inhibits its binding ability with other Sp1 proteins as well as
TATA-binding protein-associated factor II 110 (TAFII110) by pre-
venting the hydrophobic interactions between theses proteins
[134,135]. Homomultimerization of Sp1 is required to induce
Fig. 5. OGT targeting to speciﬁc proteins by adaptor/targeting proteins. (A) In the
basal state OGT does not interact with an adaptor or target protein. (B) Upon
stimulation (such as nutrient, stress, and hormone) OGT interacts with adaptor/
targeting protein(s). (C) The adaptor/targeting protein recruits OGT to its target
protein speciﬁcally increasing its rate of O-GlcNAcylation in signal dependent
manner. OGT = uridine diphospho-N-acetylglucosamine:polypeptide b-N-acetyl-
glucosaminyl transferase; G = O-GlcNAcylation.
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for binding with general transcription factor II D (TFIID), and con-
ducting DNA polymerase II dependent transcription [136]. The role
of OGT in transcription repression was later clariﬁed. By tethering
OGT to the Gal4 DNA binding domain, it was shown recruitment of
OGT to gene promoters enhanced the inhibitory effect in both basal
and Sp1-activated transcription. Later analysis showed that OGT
was recruited to promoters by another transcription repressor,
mSin3A, where HDACs interacted with the complex, resulting in
transcription repression. Truncation experiments indicated that
the ﬁrst six TPRs of OGT, which mediates protein-protein interac-
tions, are the main motif interacting with the putative paired
amphipathic helix domains of mSin3A [9,133].
Through yeast two-hybrid screens, many putative adaptor/tar-
geting proteins for OGT have been identiﬁed. Firstly, two highly
homologous proteins were isolated, (gamma-aminobutyric acid)
GABAA receptor-associated protein (GRIF-1) and OIP106 (now it is
known as Trak1). The interaction between OGT and either of these
two proteins were conﬁrmed both in vivo and in vitro. Consistent
with previous results, the ﬁrst six TPR domains of OGT are required
for interaction with these two adaptor proteins [137]. Confocal and
electron microscopy data showed that OIP106 co-localized with
RNAP II, which was further conﬁrmed by detection of a complex
among OIP106, RNAP II and OGT in HeLa nuclear extracts. This
raised the possibility that OIP106 may serve to target OGT to RNAP
II. Similarly, GRIF-1 is also thought to target OGT to GABAA [138].
A yeast two-hybrid screen using human fetal brain cDNA li-
brary, identiﬁed 27 putative OGT binding proteins. These proteins
belong to a wide range of functional classes, such as cytoskeletal
proteins, transcription factors and proteins involved in develop-
ment, and metabolism. Myosin phosphatase targeting subunit 1
(MYPT1), a known targeting regulatory subunit of PP1b, and coac-
tivator-associated arginine methyltransferase 1 (CARM1) were
conﬁrmed to interact with OGT directly and affect OGT substratespeciﬁcity in vitro. When recombinant MYPT1 or CARM1 were
mixed with OGT, in vitro O-GlcNAcylation of several proteins with-
in brain extract was increased. In contrast, in vivo knock down of
MYPT1 by RNAi decreased O-GlcNAcylation of many proteins even
though the activity of OGT and OGA were not changed. These re-
sults clearly document the importance of protein targeting to
OGT’s reaction speciﬁcity.
Several other adaptor proteins have also been reported in recent
years. Ataxin-10 interacts with OGT p110 in brain tissue, and this
interaction is competed by the mitochondrial OGT isoform, OGT
p78. In vitro OGT activity assay, using PC12 cell extracts, demon-
strates that Ataxin-10 increases OGT activity by twofold on certain
substrates [139]. These data suggest that Ataxin-10 may function
as a potential adaptor protein for OGT in vivo.
This holoenzyme complex hypothesis was also supported by
studies of the O-GlcNAcylation of several speciﬁc proteins [13,14].
For example, when Neuro-2a cells were deprived of glucose, OGT
interactswith theMAPK/p38. Through a large-scale co-immunopre-
cipitation, NF-H was identiﬁed as a substrate for both p38 and OGT.
Pharmacologically inhibiting p38 activity abolished O-GlcNAcyla-
tion of NF-H induced by glucose-deprivation, even though the inter-
action of OGT with NF-H was not changed [13].
Another well-documented OGT-adaptor protein-target protein
complex formation comes from studies of the O-GlcNAcylation of
the transcription factor FoxO1and its coactivator, PGC-1a. The inter-
action among these three proteins was conﬁrmed in cultured rat
hepatoma Fao cells. In vitro OGT assays showed that PGC-1a in-
creased OGT’s activity towards FoxO1 through increasing the inter-
action between OGT and FoxO1. High concentrations of glucose
increases O-GlcNAcylation of FoxO1 and also its transcriptional
activity in FAO cells [90]. This glucose induced increase in O-GlcNA-
cylation of FoxO1 and transcription activity were also PGC-1a
dependent.
The examples above illustrated not only the existence of OGT
adaptor/targeting proteins, but also showed that these transient
interactions are highly responsive to external signals, such as glu-
cose concentrations. Understanding the mechanisms regulating
OGT and OGA targeting to their substrates through adaptor pro-
teins will continue to be a key question for future investigations.6. Conclusion
O-GlcNAcylation plays an essential role in regulating many cel-
lular processes, such as transcription, cell signaling, metabolism
and protein stability (for reviews, Refs. [7,140,141]). Thus it is
not surprising that O-GlcNAcylation is involved in various diseases,
like cancer, diabetes, as well as neurodegenerative disease and car-
diovascular disease (for reviews, Refs. [141–143]).
The development of various rapid, highly efﬁcient technologies
forO-GlcNAc sitemapping, has enabledmore rapidadvances toward
understanding this abundant PTM. Novel detection and site map-
ping methods have uncovered the extraordinarily extensive cross-
talk or interplay between O-GlcNAcylation and phosphorylation.
Development of more direct research tools, such as site-speciﬁc O-
GlcNAc antibodies, and increases in our knowledge about the inter-
play between O-GlcNAcylation and phosphorylation, will lead to a
major paradigm shift in our understanding of signal transduction.
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